DreamCIS
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
DreamCIS is a contract research organization (CRO), a company that handles clinical trials on behalf of pharmaceutical firms that want to reduce the cost and complexity of developing new drugs.
It provides services such as trial design, consulting, monitoring, data management, and regulatory filing support to drug developers. Listed on KOSDAQ, South Korea's tech and small-cap stock exchange, it manages the full outsourced research process from early trial planning through to post-market surveillance studies.
Summary is AI-generated and may contain errors · figures from DART filings
DreamCIS in five facts
What does DreamCIS do?
DreamCIS is a contract research organization (CRO), a company that handles clinical trials on behalf of pharmaceutical firms that want to reduce the cost and complexity of developing new drugs.
Where is DreamCIS listed and in which sector?
DreamCIS (Korean name: 드림씨아이에스) trades under KRX code 223250 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is DreamCIS?
Its market capitalisation was US$78.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were DreamCIS's latest annual revenue and operating profit?
For fiscal year 2025, DreamCIS reported revenue of US$50.3M, operating profit of US$4M and net income of US$5.7M, per its annual report on DART (data retrieved from DART on 2026-09-18). Revenue was up 13.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-18
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Supply contract signed
DreamCIS updated a previously disclosed supply contract, now worth US$4.92M, about 26.55% of its recent annual revenue, running through Sep 2029.
Supply contract · Aug 11 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
DreamCIS reported consolidated results for FY2025: revenue of US$46.8M (+16% year on year), operating profit of US$4.35M (+25.2% year on year) and net income of US$5.82M (+56.6% year on year).
Earnings · Feb 11